Argus
•
Dec 11, 2024
RGNX: Raising target price to $8.00
Summary
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
SRPT: Raising target price to $17.00
Sep 02, 2026
•
SRPT
BMRN: Lowering target price to $71.00
Sep 02, 2026
•
BMRN
PTCT: Lowering target price to $67.00
Sep 02, 2026
•
PTCT
KRYS: Raising target price to $400.00
Sep 02, 2026
•
KRYS
XNCR: Lowering target price to $29.00
Sep 02, 2026
•
XNCR
